A Phase 1/2, Open-Label, Multicenter Study of INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 9
- 试验地点
- 9
- 主要终点
- Number of participants with Dose Limiting Toxicities (DLTs)
研究概览
简要总结
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Anticipated life expectancy greater than 12 weeks.
- •ECOG performance status score of 0 or
- •Measurable disease per RECIST v1.1 on CT or MRI.
- •Part 1a and 2a (dose escalation) and Part 1c (dose expansion): participants who have a confirmed tissue diagnosis of a solid malignant tumor that is progressing and not amenable to curative surgery or other curative treatment modalities.
- •Part 1a (monotherapy): Participants must have had disease progression on/after prior treatment and have been considered for all standard available therapies (have disease progression on all available standard treatment options or are intolerant or ineligible to them or has refused available options approved in the region).
- •Part 2a (combination): participants with advanced malignant tumors for whom immunotherapy is an appropriate treatment option.
- •Part 1b incurable locally recurrent or metastatic HNSCC:
- •Tissue diagnosis of HNSCC.
- •Locally recurrent disease must not be amenable to therapy (surgery and/or radiation therapy with or without chemotherapy) with curative intent. Participants who refuse curative salvage surgery for locally recurrent disease are ineligible.
- •Eligible primary tumor locations include oral cavity, oropharynx, hypopharynx, or larynx. Primary tumors of the nasopharynx, sinonasal cavity, or salivary gland are excluded.
- •Part 2b combination dose-expansion cohorts in locally advanced or metastatic SCAC (Group 1), metastatic PD-L1-positive (TPS ≥ 50%) NSCLC (Group 2), or locally recurrent or metastatic PD-L1-positive (CPS ≥ 1%) HNSCC (Group 3) (Primary tumors of the nasopharynx, sinonasal cavity, or salivary gland are excluded).
- •Availability of a baseline archival tumor specimen or willingness to undergo a pretreatment biopsy to obtain.
- •If HIV-positive, CD4+ count must be greater than or equal to 350 cells/μL, must have undetectable viral load per standard of care assay, and receiving antiretroviral therapy not containing a moderate or potent CYP3A4/CYP3A5 inhibitor or inducer for at least 4 weeks prior to study enrollment, and have not had any HIV-related opportunistic infection for at least 4 weeks prior to study enrollment.
- •Willingness to avoid pregnancy or fathering children.
排除标准
- •Known additional invasive malignancy within 1 year of the first dose of study drug.
- •Known active CNS metastases and/or carcinomatous meningitis and/or leptomeningeal disease, or evidence of progression of previously treated CNS metastases.
- •Prior treatment with a DGK inhibitor.
- •Receipt of anticancer medications, investigational drugs, or other interventional clinical studies within 5 half-lives or 28 days before the first administration of study drug.
- •History of organ transplant, including allogeneic stem cell transplantation.
- •Radiation therapy administered within 28 days of the start of treatment.
- •Any residual toxic effects ≥ Grade 2 from prior therapy or surgery.
- •Any immune-related toxicity during prior immune therapy for which permanent discontinuation or prolonged immunosuppression was recommended to manage.
- •Laboratory values specified at screening.
- •Significant concurrent, uncontrolled medical conditions, including but not limited to hepatic, gastrointestinal conditions, pulmonary, cardiovascular, and active autoimmune disease.
- •Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
- •Active HBV or HCV.
- •Prohibited medication per protocol.
- •Hypersensitivity to any component of study treatment or formulation components.
- •Women who are pregnant or breastfeeding.
- •Has received a live vaccine within 28 days of the planned start of study treatment.
- •Any condition that would interfere with participation.
- •Other protocol-defined Inclusion/Exclusion Criteria may apply.
研究组 & 干预措施
Part 1a: Dose Escalation monotherapy
INCB177054 at the protocol-defined dose strength based on cohort assignment.
干预措施: INCB177054 (Drug)
Part 1b: Pharmacodynamic cohort
INCB177054 at the protocol-defined dose strength based on cohort assignment.
干预措施: INCB177054 (Drug)
Part 1c: Dose Expansion monotherapy
INCB177054 at the protocol-defined dose strength based on cohort assignment.
干预措施: INCB177054 (Drug)
Part 2a: Dose Escalation combination
INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment.
干预措施: INCB177054 (Drug)
Part 2a: Dose Escalation combination
INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment.
干预措施: Retifanlimab (Drug)
Part 2b: Dose Expansion combination
INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment.
干预措施: INCB177054 (Drug)
Part 2b: Dose Expansion combination
INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment.
干预措施: Retifanlimab (Drug)
结局指标
主要结局
Number of participants with Dose Limiting Toxicities (DLTs)
时间窗: Up to 28 days
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Number of participants with Treatment-emergent Adverse Events (TEAEs)
时间窗: Up to approximately 12 months and 45 days
Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
Number of participants with TEAEs leading to study drug modifications
时间窗: Up to approximately 12 months and 45 days
Number of participants with TEAEs leading to dose modification including interruptions, dose reductions, and discontinuation of study drug.
次要结局
- Disease Control(Up to approximately 12 months)
- Objective Response(Up to approximately 12 months)
- Duration of Response(Up to approximately 12 months)